Determination of hepatitis C genotypes and the viral titer distribution in children and adolescents with major thalassemia

Iranian Journal of Pediatrics

Volumn 20, Issue 1, 2010, Pages 75-81

  Shahraki, Touran ^a   Shahraki, Mansour ^b   Moghaddam, Esmaiel Sanei ^c   Najafi, Mehri ^d   Bahari, Ali ^a  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c High Institute for Research and Education in Transfusion Medicine   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis C; Iran; Liver function tests; Thalassemia; Viral load; Virus titer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; FERRITIN; RNA;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD SAMPLING; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FUNCTION; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

EID: 77749334428     PISSN: 10184406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol. 2000;30(2):125-43.
2. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody negative blood donors by nucleic acid amplification testing. N Engl J Med. 2004;351(8):760-8.
3. Ladis V, Chouliaras G, Berdousi H, et al. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005;1054:445-50.
4. Prati D. Benefits and complications of regular blood transfusion in patients with beta thalassaemia major. Vox Sang. 2000;79(3):129-37.
5. Süoǧlu D, Elkabes B, Sökücü S, Saner G. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C? J Pediatr Gastroenterol Nutr. 2002;34(2):199-206.
6. Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002;36(5):1280-4.
7. Hartman C, Berkowitz D, Rimon N, Shamir R. The effect of early treatment in children with chronic hepatitis. J Pediatr Gastro enterol Nutr. 2003;37(3):252-7.
8. Ghavanini AA, Sabri MR. Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran. East Mediterr Health J. 2000;6(5 6):1114-6.
9. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case control study. J Gastroenterol Hepatol. 2002;17(10):1092-97.
10. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat. 2002;9(5):390-2.
11. Mirmomen S, Alavian SM, Hajarizadeh B, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9(4):319-23.
12. Karimi M, Ghavanini AA. Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus antibodies among multitransfused thalassaemic children in Shiraz, Iran. J Paediatr Child Health. 2001;37(6):564-6.
13. Zein NN, Persing DH. Hepatitis C genotypes: current trends and future implications. Mayo Clin Proc. 1996;71(5):458-62.
14. Smith DB, Simmonds P. Review: molecular epidemiology of hepatitis C virus. J Gastroenterol Hepatol. 1997;12(7):522-7.
15. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13(2):223-35.
16. Izopet J, Payen JL, Alric L, et al. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha interferon therapy. J Med Virol. 1998;54(2):86-91.
17. Hosogaya S, Ozaki Y, Enomoto N, Akahane Y. Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C. Transl Res. 2006;148(2):79-86.
18. Gervais A, Martinot M, Boyer N, et al. Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment. J Hepatol. 2001;35(3):399-405.
19. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 1992;73(pt 3):673-9.
20. Roudbari M, Soltani Rad M, Roudbari S. The survival analysis of beta thalassemia major patients in South East of Iran. Saudi Med J. 2008;29(7):1031-5.
21. Vrielink H, van der Poel CL, Reesink HW, et al. Transmission of hepatitis C virus by anti HCV negative blood transfusion. Case report. Vox Sang. 1995;68(1):55-6.
22. Manesis EK, Papaioannou C, Gioustozi A, et al. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow up of 211 patients. Hepatology. 1997;26(3):734-9.
23. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995;22(4 pt 1):1326-9.
24. Alavian SM, Miri SM, Keshvari M, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion. 2009;49(10):2195-9.
25. Keyvani H, Alizadeh AH, Alavian SM, et al. Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res. 2007;37(2):101-3.
26. Siagris D, Giannakoulas N, Christofidou M, et al. Virological, immunological and histological aspects in adult beta thalassemic patients with chronic hepatitis C virus infection. Liver Int. 2004;24(3):204-9.
27. Di Marco V, Lo Iacono O, Almasio P, et al. Long term efficacy of alpha-interferon in beta thalassemics with chronic hepatitis C. Blood. 1997;90(6):2207-12.
28. Chakravarti A, Verma V. Distribution of hepatitis C virus genotypes in beta-thalassaemic patients from Northern India. Transfus Med 2006;16(6):433-8.
29. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis. 2000;20(1):103-26.
30. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med. 1996;125(8):658-68.
31. Svirtlih N, Delic D, Simonovic J, et al. Hepatitis C virus genotypes in Serbia and Montenegro: the prevalence and clinical significance. World J Gastroenterol. 2007;13(3):355-60.
32. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 1996;125(8):634-9.
33. Martinot Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995;22(4 pt 1):1050-6.
34. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol. 1990;43(8):638-40.
35. Ameli M, Besharati S, Nemati K, Zamani F. Relationship between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran. Saudi Med J. 2008;29(11):1611-5.
36. Prati D, Zanella A, Farma E, et al. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta thalassemia. Blood. 1998;92(9):3460-4.